AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Impact · against what's priced in

The article provides no new catalysts for Eli Lilly or AbbVie, as the financial results and growth trajectories reported were already incorporated into the current valuations. The data confirms the expected transition from Humira to Skyrizi for AbbVie and the continued scaling of cardiometabolic therapies for Lilly without altering their long-term growth assumptions.

LLY+0.00

Already priced in

The price assumes

A deceleration in growth from the 44.7% just delivered down to the 30.2% the reverse-DCF requires